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HLA alloimmunization is a major causeofthe platelet refractory state. The stimulus for HLA
alloimmunization is believed to derive from incompatibility between the recipient's lymphocytes
and the passenger donor lymphocytes contained in transfused red cells or platelet concentrates.
Two techniques to prevent post-transfusion HLA alloimmunization include filtration, which
physically removes the donor lymphocytes, and UV-B irradiation, which renders the donor
leukocytes biologically inactive. The role of these two techniques in the prevention of HLA
alloimmunization is the focusofthis review.
Due to the development of blood component therapy and the ready availability of
platelet transfusions, thrombocytopenic patients who previously would have suffered a
fatal hemorrhage can now be treated. Access to platelet transfusions, for example,
permits oncology patients to complete a prescribed course of chemotherapy and in
many situations survive for long disease-free periods. The ready availability ofplatelet
concentrates (PC), however, has generated a new concern regarding the development
of the platelet refractory state. With this condition, platelet transfusions, which
formerly were effective, no longer provide an appropriate post-transfusion platelet
count increment. Platelet refractoriness, in general, refers to the inability to obtain an
appropriate elevation in platelet count following transfusion. The causes ofrefractory
state are manifold and are listed in Table 1. Ofthese myriad causes, HLAalloimmuni-
zation represents one area which is the current focus of intense biomedical research.
The relative contribution ofmanyoftheother factors has recently been reviewed [1,2].
The prevention of platelet refractoriness due to HLA alloimmunization will be the
subject ofthis review.
Various guidelines have been developed to aid in determining an appropriate
post-transfusion platelet count increment. For adults, one such guideline is to expect a
rise in platelet count of5,000-10,000/,gL for every unit ofplatelets transfused. Such a
figure, however, is inappropriate when comparing post-transfusion increments in
patients of very small physical stature, such as pediatric patients, with obese or very
large adult patients. Accordingly, more complex formulas have been developed. One
such formula, a corrected count increment (CCI), is as follows:
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such formula, a corrected count increment (CCI), is as follows:
Post-transfusion platelet count - Pre-transfusion platelet count
CCI = Platelets transfused x 1011 x BSA (n2)
where BSA = body surface area.
This formula permits comparisons between individuals of different body sizes, as
well as between transfusions in which different amounts ofplatelets were infused.
The etiology of a low post-transfusion platelet count requires clinical investigation.
One cause, which has become ofincreasing importance to physicians, is refractoriness
due to HLA alloimmunization. The HLA antigen system includes two classes of
molecules: Class I molecules, the HLA-A, -B, and -C loci antigens which are present
on leukocytes as well as on platelets, and Class II D locus antigens, including DR, DP,
and DQ, which are present only on leukocytes [3,4]. According to current theory,
primary HLA alloimmunization isacomplexprocess, dependent on recognitionofboth
HLA Class I and Class II antigenic differences [3,5,6]. The presence of viable cells
bearing Class II antigens such aslymphocytes and antigen-presenting cells is necessary
to stimulate primary HLA alloimmunization [4,7] (see Fig. 1). Antigen-presenting
cells include monocytes, macrophages, dendritic cells, and B cells. When blood is
transfused, thelackofidentitybetweendonorand recipientlymphocytes attheClass II
(D) locus stimulates the recipient to produce antibody against donor Class I HLA
antigens [4,7]. This anti-Class I antibody is often responsible for a poor CCI, because
Class I HLA antigens are present on platelets. Since it is the incompatibility between
recipient and donor leukocytes which initiates the alloimmunization process, platelets
can be considered to be "innocent bystanders." Researchers have hypothesized that,
since platelets lack Class II antigens and are not the source of the immunogenic
stimulus, if ways were found either to remove the Class II-carrying leukocytes
physically or to inactivate them, perhaps HLA alloimmunization could be prevented
[5]. This method will not, however, prevent the formation ofplatelet-specific alloanti-
body, which is due to transfusion of incompatible platelet antigens. Although the
incidence of refractoriness due to platelet-specific antibody is much smaller, there is
active research in this area, too [8,9,10].
LEUKOCYTE-REMOVAL FILTERS
A number of published articles have shown that removal of white cells from blood
components prevents, or at leastdelays, theonsetofHLAalloimmunization [5,11-18].
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FIG. 1. Schematic representation of the molecular interactions that occur between
donor monocytes (APC) and recipient T cells during the early stages of immune
responsiveness. The various accessory molecules involved in the interaction are also
shown. Reproduced with permission ofthe publisher from [42].
Based on the data presented in these papers, the degree ofwhite cell removal required
is at least two to three logs (99.0-99.9 percent). This degree of removal applies to all
leukocyte-containing blood components, including platelet concentrates and red blood
cells. Units of red blood cells contain up to 109 white cells, and after filtration or
washing there are more than 107 white cells still remaining. Based on clinical
observations, these remaining white cells are sufficient to stimulate the development of
HLA antibody.
Removal ofwhite cells can be achieved by several means, which include centrifuga-
tion, with or without cell washing, or the use of blood filtration technology [11].
Centrifugation with buffy coat removal and/or automated cell washing is relatively
inefficient, removing at best 1-2 logs ofwhite cells (90-99.0 percent). This percentage
of removal, however, still leaves 7-8 logs of white blood cells in the red cell unit, a
number which is probably sufficient to stimulate HLA antibody formation. Newly
designed third-generation blood filters have been developed which are capable of
removing up to 3 logs (99.9 percent) ofcontaminated leukocytes [19-21].
The first blood filters produced were coarse clot screens, which had pore sizes of
170-260 Am; they weredesigned primarily to remove clots and debris which formed in
blood during storage [22]. These filters are in widespread use due to the FDA and
American Association ofBlood Banks requirement that, to removeprotein coagula and
otherdebris, all blood components be infused through an administration setcontaining
a filter. These filters, however, remove less than 1 log (<90 percent) of the leukocyte
aggregates and are unable to remove individual white cells, which are about 8-14 ,um
in diameter. Second-generation microaggregate filters, both the screen and the depth
types, are capable of removing microaggregates (fragments of deteriorated platelets,
leukocytes, and fibrin strands) in the size range of 20-120 um [22]. They can remove
up to 1-2 logs (90-97 percent) ofthe leucocytes from units ofred cells most efficiently
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when the blood product is centrifuged and held at 40C prior to filtration (spin-cool-
filter technique) [11,23]. Most efficient 3 log (99.9 percent) white cell removal is
achieved, however, only with use ofthird-generation leucocytedepletion filters.
Third-generation filters employ technology which involves coating the filter fibers
with chemical polymers [19-21]. These polymers impart various surface tension and
adsorption characteristics to the fibers, which make the filtration process highly
efficient in terms ofthe number ofcells removed as well as highly selective in terms of
the specific type of cell removed. Changing the polymer coating on the fiber results in
the ability to remove different numbers as well as different types of cells. One type of
filter will remove both leukocytes and platelets from units of red cells [19], while
another type will selectively removeleukocytesfrom units ofplatelet concentrates [20].
Ifthe wrong filter is used, however, the wrong cell may be removed. Forexample, ifone
desires to leukocyte deplete a pool ofplatelets, filtration ofthe platelet concentratepool
through a filter designed to leukocyte deplete red blood cells will result in platelet as
well as white cell removal. Thus, this particular recipient essentially will receive
platelet-poor plasma [21].
As mentioned, various studies have shown that removal ofwhitecells to a level below
106 or 105 appears to prevent or delay alloimmunization [5,11-18]. Several questions
remain, however. First, the long-term cumulative effects of transfusing third-
generation filtered blood components containing less than 105 and 106 white cells are
unknown. Perhaps use of these filters merely postpones the onset of HLA alloimmuni-
zation; further data are needed [5]. Although delay in the onset ofalloimmunization is
appropriate in itself, iflong-term benefits are not obtainable through use ofthe filters,
then any advantage from their use may not be balanced by the current $30-$60 cost
per filter.
The indiscriminate use of these third-generation filters cannot be recommended
because many patients may not be helped by the use of such a filter [24]. Multiparous
women, for example, are exposed to paternal HLA antigens at parturition, following
the entry offetal white cells into maternal circulation; such women are at high risk for
developing HLA alloantibodies [14]. Even these highly efficient white cell depletion
filters thus provide no protection for previously pregnant women patients who have
already been exposed to HLA antigens during the birth oftheirchildren, and who may
already have developed HLA alloantibody [14]. If a sufficient number of antigen-
presenting cells were infused during previous blood transfusions that a patient received
prior to the current illness, the patient, again, may already have developed HLA
alloantibodies and would not benefit from the use ofwhite cell depletion filters. Studies
have shown that up to 50 percent of multiply transfused patients will develop HLA
antibodies [5,25-28]. Thus it is possible that many patients may already be HLA
alloimmunized when they present to their physicians. Furthermore, data show that
40-50 percent of patients are non-responders and are unlikely ever to develop HLA
antibodies [29]. Aspecial third-generation leukocytedepletion filter would be unneces-
sary for such patients.
The criteria for diagnosing HLA alloimmunization rest on the finding of a positive
test for HLA antibody. No one test, however, is sufficiently sensitive. Accordingly, a
negative finding with one type of assay does not rule out the possibility that HLA
antibody might actually be present. Most experts agree, therefore, that several types of
HLA antibody assays should be performed and found to be negative before HLA
alloimmunization is eliminated as a cause for a poor post-transfusion CCI.
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The exact number of white cells necessary to trigger the immune response is not
known. As morestudies areperformed evaluating theroleofleukocytedepletion filters,
a clearer picture will emerge regarding the role ofleukocyte removal in prevention of
HLA alloimmunization. Even if every white cell could be removed from every unit of
platelet concentrate and red blood cells, however, platelet refractoriness would still
exist because many of the causes of poor post-transfusion platelet count increments
(Table 1) are not related to HLA antibody at all but to the myriad of other factors
mentioned previously [1,2].
UV-B IRRADIATION
Another typeoftechnology that may prevent ordelay theonsetofHLAalloimmuni-
zation in transfused patients is the use of UV-B (ultraviolet B) irradiation [30-32].
Instead of removing the Class II antigen-containing leukocytes as filters do, UV-B
irradiation appears to inactivate Class II molecules present on donor antigen-
presenting cells, thus inhibiting recipient recognition of the transfused donor cells as
being foreign. This process of UV-B irradiation is adequate for inactivation of
leukocytes in units of platelet concentrate. Because hemoglobin absorbs light in the
UV-B spectral range, however, effective UV-B irradiation ofthe white cells present in
full units of red cell products cannot be achieved with existing technology. The UV-B
cannot penetrate farther than a few millimeters into the red cells; thus, most oftheunit
fails to receive any radiation. To radiatewhole blood effectively, a thin layer ofblood is
needed, and the cross-sectional diameter of the layer of blood to be UV irradiated
should not exceed several millimeters. Thus, for full units of whole blood or red cell
products, third-generation filters still must be used to remove the leukocytes physically.
Two published studies have shown in dog models that transfusions ofUV-irradiated
blood products do not stimulate HLA alloimmunization [33,34]. Deeg et al. [33],
using a donordog, transfused wholeblood which wasexposed to UVlight in adosageof
1.35 J/cm2. The blood to be transfused was placed in a sterile petri dish and then
exposed to the ultraviolet source. Since small aliquots of blood were used, the UV
radiation adequately penetrated theblood andthuseffectively irradiated anycontained
white cells. The recipient dogs were given three transfusions of UV-treated blood
followed by a bone marrow graft from the DLA-identical transfusion donor dog. All
recipient dogs so treated achieved sustained engraftment. For the control group,
however, sham exposure of the donor dog blood to visible light failed to prevent
alloimmunization, and all control dogs rejected their grafts.
Slichter et al. [34], in a study ofthe immunosuppressive effects ofUV irradiation of
platelet concentrates, provided weekly UV-irradiated platelet transfusions from a
single random donor dog to a recipient dog. After eight weekly transfusions, ofthe 12
recipientdogs studied, 92 percent (11) remained non-immunized. In the control group,
however, of the dogs who received eight weekly transfusions of non-UV-irradiated
platelet concentrates, only 14 percent were non-immunized at the end of the eight
weeks. Thus, UV irradiation ofdonor platelets was markedly successful in preventing
alloimmunization. Furthermore, two-thirds (67 percent) of the non-alloimmunized
dogs who had previously received UV-irradiated platelets remained un-immunized
after receiving an additional eight non-UV-irradiated transfusions from their same
donors; this fact suggests the induction of a state of tolerance. This result raises
concerns, however, regarding the possible paralysis of the patient's immune system,
making the recipient ofUV-irradiated blood components susceptible to infections with
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a variety of bacterial, viral, or fungal agents. Animals receiving UV-irradiated blood
products, however, can make antibody to sheep red blood cells as well as to various
bacteria; thus their immune systems are not totally paralyzed following use of
UV-irradiated blood products.
The exact mechanism of UV-B inactivation is unclear. Some believe it relates to
interference with movement ofcalcium in the cell membrane [32]. Initially it had been
thought that the protective effect was related to the loss or shedding of Class II
antigens from the donor APC induced by the UV-B irradiation. This concept has been
challenged by other investigators, however, and definitive studies are lacking [5,35].
Recent work implicates loss of ICAM-1 from the surface ofAPC monocytes following
UV-B irradiation [36]. ICAM-1 is an accessory adhesive molecule involved in stabili-
zation of the donor APC and recipient T-cell complex [36]. Human clinical trials are
currently being performed to evaluate the ability ofUV-B irradiation to prevent onset
of alloimmunization; there are insufficient data at present to reach conclusions. It is
likely, however, that parous women will need to be studied separately to ensurethat the
lack of development of HLA antibody in these patients is not due to their being
"non-responders" whowould not have made antibody [29].
Another area of UV-B research involves irradiation of bone marrow. In an attempt
to prevent graft-versus-host disease, scientists are evaluating the effect of UV-B
radiation on bone marrow. Published data show that UV-B light can be used to
inactivate bonemarrow Tlymphocytes selectively, whilesparing hematopoieticprecur-
sor cells [37]. Further clinical studies are in progress.
Another problem related to the use of UV-B irradiation of platelet concentrate
concerns the ability to store such concentrates. Platelet concentrates can be stored for
up to 120 hours (five days) at 20-240C with continuous gentle agitation. If UV-B
irradiation is to be most useful in modern transfusion medicine, it would bedesirable to
be able to store the irradiated platelets prior totransfusion. Thisprocedurewould allow
for ease ofhandling by blood centers or major hospitals which must supply products to
other institutions that may not have the facilities to UV-B irradiate platelet concen-
trates. Several studies have been published, one by Pamphilon et al. [31] showing that,
following a low dose of UV-B irradiation (300 mJ/cm2), platelets appeared to store
well over five days. Another study by Snyder et al. [38], showed that, at a higher dose
(10,000 mJ/cm2), while there were no significant adverse changes seen after 48 hours
of storage, when platelets had been stored for four days after having been UV-B
irradiated, significant changes in platelet storage characteristics were observed. These
changes included a sharp decline in morphology and osmotic recovery scores, a loss of
surface immunoreactive GP Tb, and a change in 2D-PAGE patterns of solubilized
whole platelets. Thus, dose effects appear to play a role in maintenance of platelet
integrity during storage after UV-B irradiation. Lastly, Andreu et al. [39] published
thefinding that UV-B irradiation at energy levels below 3 J/cm2did notimpairplatelet
function.
Prevention of HLA alloimmunization by the use ofthird-generation filters or UV-B
irradiation appears feasible. There are manyrefractorypatients who are notalloimmu-
nized, however (refer to Table 1), and physicians and other health care personnel must
remember that unqualified claims, implying that use of a filter or an irradiation
technique will prevent refractoriness in all patients, are exaggerated. Such claims can
refer only to individuals who are not yet alloimmunized and even then only to the
possible ability to prevent or merely to delay the onset of HLA antibody formation. It
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should not be misconstrued to mean that these techniques will be of benefit to patients
with any of the many other causes of platelet refractoriness outlined in Table 1. The
distinction between refractoriness to platelet transfusion and HLA alloimmunization
as one cause ofrefractoriness must be remembered.
One last area ofcontroversy associated with prevention ofHLA alloimmunization is
the loss of a possible graft-versus-leukemia effect following the use of leukocyte-poor
blood components. Tucker et al. [40] raised concerns that the use of leukocyte-poor
blood components to prevent HLA alloimmunization could also prevent a so-called
"graft-versus-leukemia" effect. This theory states that lymphocytes which are con-
tained in red cell or platelet transfusions may be useful in fighting the residual
leukemia in the recipient in the form ofgraft-versus-host (leukemia) disease. Removal
of the white cells may inhibit this reaction, thus decreasing rates of remission and
survival ofrecipients ofsuch blood components. Moreinformation is needed before one
can decide whether this idea is a valid concern. Evidence for an antileukemic effect of
bone marrow transplantation not explained by the associated high-dose chemotherapy
and/or radiotherapy has recently been published by Horowitz et al. [41].
CONCLUSIONS
This review has addressed an area oftransfusion medicine practice which is involved
with the development ofthe immune response. Modulation ofthe immune response by
removal of white cells or by inactivation of various antigens on the white cells which
play a key role in initiation of the immune response in an area of active research.
Achieving and maintaining an appropriate post-transfusion corrected count increment
by prevention of HLA alloimmunization is an important goal. Even though the
prevention of HLA alloimmunization will not completely eliminate the refractory
state, it will, to a large degree, make medical care for patients requiring platelet
transfusions more efficient and more effective.
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